50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
How You Should Be Choosing Your Stocks (Ad)pixel
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
How You Should Be Choosing Your Stocks (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
How You Should Be Choosing Your Stocks (Ad)pixel
Can Caterpillar Claw Higher in a Falling Market?
Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
How You Should Be Choosing Your Stocks (Ad)pixel
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
How You Should Be Choosing Your Stocks (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
How You Should Be Choosing Your Stocks (Ad)pixel
Can Caterpillar Claw Higher in a Falling Market?
Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
How You Should Be Choosing Your Stocks (Ad)pixel
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
How You Should Be Choosing Your Stocks (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
How You Should Be Choosing Your Stocks (Ad)pixel
Can Caterpillar Claw Higher in a Falling Market?
Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Get 1TB of Top-Rated Cloud Storage for Life for Just $112
How You Should Be Choosing Your Stocks (Ad)pixel
Germany secures more gas shipments as Scholz visits Gulf
Labour conference starts with focus on 'immoral' tax cuts
How You Should Be Choosing Your Stocks (Ad)pixel
German leader continues Gulf tour with stops in UAE, Qatar
Fire breaks out at world's biggest produce market in Paris
How You Should Be Choosing Your Stocks (Ad)pixel
Can Caterpillar Claw Higher in a Falling Market?
Should These 3 Top-Performing Mid-Caps Be On Your Watchlist?
NASDAQ:VKTX

Viking Therapeutics - VKTX Stock Forecast, Price & News

$2.66
-0.19 (-6.67%)
(As of 09/23/2022 08:56 PM ET)
Add
Compare
Today's Range
$2.62
$2.86
50-Day Range
$2.66
$3.89
52-Week Range
$2.02
$7.05
Volume
686,400 shs
Average Volume
990,330 shs
Market Capitalization
$203.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.50

Viking Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
407.5% Upside
$13.50 Price Target
Short Interest
Healthy
2.96% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.88
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.92) to ($1.12) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

565th out of 1,075 stocks

Pharmaceutical Preparations Industry

261st out of 532 stocks

VKTX stock logo

About Viking Therapeutics (NASDAQ:VKTX) Stock

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Stock News Headlines

Viking Therapeutics: Playing Second Fiddle To Madrigal
Viking Therapeutics Misses Q1 EPS by 2c
Revisiting Viking Therapeutics
Viking Therapeutics rises 8% following Q4 results
See More Headlines
Receive VKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Viking Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VKTX Company Calendar

Last Earnings
7/27/2022
Today
9/25/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VKTX
Fax
N/A
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$13.50
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+407.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-54,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.58 per share

Miscellaneous

Free Float
72,470,000
Market Cap
$203.99 million
Optionable
Optionable
Beta
1.36

Key Executives

  • Dr. Brian Lian Ph.D. (Age 56)
    Pres, CEO & Director
    Comp: $872k
  • Mr. Gregory S. Zante (Age 51)
    Chief Financial Officer
    Comp: $536k
  • Ms. Marianne Mancini (Age 57)
    Chief Operating Officer
    Comp: $543k
  • Mr. Michael Morneau (Age 57)
    VP of Fin. & Admin.













VKTX Stock - Frequently Asked Questions

Should I buy or sell Viking Therapeutics stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Viking Therapeutics in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VKTX shares.
View VKTX analyst ratings
or view top-rated stocks.

What is Viking Therapeutics' stock price forecast for 2022?

5 Wall Street analysts have issued 1 year target prices for Viking Therapeutics' stock. Their VKTX share price forecasts range from $10.00 to $15.00. On average, they predict the company's stock price to reach $13.50 in the next year. This suggests a possible upside of 407.5% from the stock's current price.
View analysts price targets for VKTX
or view top-rated stocks among Wall Street analysts.

How have VKTX shares performed in 2022?

Viking Therapeutics' stock was trading at $4.60 at the beginning of the year. Since then, VKTX stock has decreased by 42.2% and is now trading at $2.66.
View the best growth stocks for 2022 here
.

When is Viking Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our VKTX earnings forecast
.

How were Viking Therapeutics' earnings last quarter?

Viking Therapeutics, Inc. (NASDAQ:VKTX) posted its earnings results on Wednesday, July, 27th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.02.

What other stocks do shareholders of Viking Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Viking Therapeutics investors own include NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), SCYNEXIS (SCYX), Amarin (AMRN), Advanced Micro Devices (AMD), Verastem (VSTM), Energy Transfer (ET) and Inovio Pharmaceuticals (INO).

When did Viking Therapeutics IPO?

(VKTX) raised $20 million in an initial public offering (IPO) on Wednesday, April 29th 2015. The company issued 2,500,000 shares at $7.00-$9.00 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO and Feltl and Company was co-manager.

What is Viking Therapeutics' stock symbol?

Viking Therapeutics trades on the NASDAQ under the ticker symbol "VKTX."

Who are Viking Therapeutics' major shareholders?

Viking Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Laurion Capital Management LP (1.73%), Millennium Management LLC (1.71%), Renaissance Technologies LLC (1.13%), Ikarian Capital LLC (1.09%), DAFNA Capital Management LLC (0.60%) and Cubist Systematic Strategies LLC (0.43%). Insiders that own company stock include Ligand Pharmaceuticals Inc and Matthew W Foehr.
View institutional ownership trends
.

How do I buy shares of Viking Therapeutics?

Shares of VKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Viking Therapeutics' stock price today?

One share of VKTX stock can currently be purchased for approximately $2.66.

How much money does Viking Therapeutics make?

Viking Therapeutics (NASDAQ:VKTX) has a market capitalization of $204.00 million. The biotechnology company earns $-54,990,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How can I contact Viking Therapeutics?

Viking Therapeutics' mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The official website for the company is www.vikingtherapeutics.com. The biotechnology company can be reached via phone at (858) 704-4660 or via email at sdiaz@vidasp.com.

This page (NASDAQ:VKTX) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.